Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Endocrinology›Condition·Updated Jun 27, 2026·v1

Hypercalcemia

Hypercalcemia is a severity- and etiology-driven metabolic emergency. The PTH level is the critical diagnostic branch point. Acute management focuses on volume expansion, calcitonin for rapid reduction, and bisphosphonates/denosumab as definitive antiresorptive therapy. Long-term treatment targets the underlying cause: parathyroidectomy for PHPT, bisphosphonates/denosumab for malignancy, glucocorticoids for granulomatous disease. Prognosis varies widely, mild PHPT has excellent outcomes, while malignancy-associated hypercalcemia carries high short-term mortality.

High Evidence138 references·1,430 words·6 min read·v1
hypercalcemiaprimary hyperparathyroidismhypercalcemia of malignancyPTHPTHrPcalcitriolfamilial hypocalciuric hypercalcemiabisphosphonatesdenosumabzoledronic acidparathyroid carcinomaMEN1sarcoidosis

Quick Reference

RxDrug of choiceZoledronic acid 4 mg IV over 15 minutes (first-line for malignancy-associated hypercalcemia; also used in severe PHPT).
AltAlternativesDenosumab 120 mg SC (for bisphosphonate-refractory cases or renal impairment); pamidronate 60-90 mg IV (less potent than zoledronic acid); calcitonin 4-8 IU/kg IM/SC q6-12h (rapid but transient).
⊘AvoidPhosphate supplements (precipitate calcium phosphate crystals); loop diuretics unless volume overloaded (exacerbate dehydration); zoledronic acid in CrCl <35 mL/min; fine-needle aspiration of suspected parathyroid carcinoma.
DxTest of choiceIntact PTH level, the single most important test to narrow the differential.
ScKey scoreCalcium-to-creatinine clearance ratio (CCCR) <0.01 suggests FHH; >0.02 suggests PHPT.
→When to referPHPT meeting surgical criteria (Ca >1 mg/dL above ULN, CrCl <60, T-score ≤-2.5, age <50) or symptomatic; suspected parathyroid carcinoma; FHH or MEN1 for genetic counseling; persistent hypercalcemia despite bisphosphonates.
Hypercalcemia is managed acutely by severity and definitively by targeting the underlying axis: parathyroidectomy for PHPT, bisphosphonates/denosumab for malignancy, glucocorticoids for granulomatous disease.
Hypercalcemia is a common electrolyte disorder defined as total serum calcium >10.5 mg/dL (2.6 mmol/L) after albumin correction or ionized calcium >1.32 mmol/L. [[Primary hyperparathyroidism]] (PHPT) and malignancy account for >90% of cases [3]. Severity is stratified into mild (10.5-11.9 mg/dL), moderate (12.0-13.9 mg/dL), and severe (≥14.0 mg/dL). The PTH level is the single most important diagnostic test to distinguish PTH-dependent from PTH-independent causes [3].

Overview and Recommendations

Background

  • •Hypercalcemia is defined as a total serum calcium >10.5 mg/dL (2.6 mmol/L) after correction for albumin, or an ionized calcium >1.32 mmol/L. It is a common electrolyte abnormality encountered across inpatient and outpatient settings, with (PHPT) and malignancy accounting for more than 90% of cases [3].
  • •Primary hyperparathyroidism (PHPT) affects 1 to 7 per 1,000 adults, with a female-to-male ratio of ~3:1 and incidence peaking in the fifth to sixth decade. Malignancy-associated hypercalcemia (HCM) is the most common metabolic complication of advanced solid tumors (lung, breast, renal, head/neck) and hematologic malignancies (multiple myeloma, lymphoma), and is the dominant cause in hospitalized patients [19, 38, 44].
  • •The calcium-PTH-vitamin D axis is exquisitely regulated by the calcium-sensing receptor (CaSR) on parathyroid chief cells. Every cause of hypercalcemia arises from one or more of three pathophysiologic nodes: excessive bone resorption, increased intestinal calcium absorption, or decreased renal calcium excretion. The biochemical signature, defined by PTH, PTHrP, 1,25-dihydroxyvitamin D, and phosphate, fingerprints the specific etiology [11, 20].
  • •Hypercalcemia is not a diagnosis but a biochemical clue. The single most important initial test is the intact PTH level: an elevated or inappropriately normal PTH defines PTH-dependent hypercalcemia (PHPT, FHH, lithium therapy); a suppressed PTH (<20 pg/mL) defines PTH-independent hypercalcemia, dominated by malignancy (PTHrP), granulomatous disease (calcitriol), or vitamin D intoxication. The CCCR (<0.01 suggests FHH; >0.02 suggests PHPT) resolves the most common diagnostic ambiguity [3, 13].

Evaluation

  • •Suspect hypercalcemia in any patient with fatigue, cognitive slowing, depression, constipation, polyuria, polydipsia, or kidney stones; in hospitalized patients with advanced cancer or critical illness, check a calcium level at admission [68, 29].
  • •Ask about a history of kidney stones, fragility fractures, prior neck surgery, lithium or thiazide use, high-dose vitamin D or calcium supplementation, granulomatous disease (sarcoidosis, tuberculosis), and family history of hypercalcemia or endocrine tumors [3, 44].
  • •Confirm hypercalcemia with a repeat albumin-corrected total calcium or ionized calcium. Calculate corrected Ca (mg/dL) = measured total Ca + 0.8 × (4.0 - albumin). Severity staging: mild 10.5-11.9 mg/dL, moderate 12.0-13.9 mg/dL, severe ≥14.0 mg/dL [38, 99].
  • •Order the paired biochemical profile on a single morning blood draw: albumin-corrected calcium, intact PTH, phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, creatinine, and a 24-hour urine for calcium, creatinine, and sodium. Interpretation hinges on the PTH-calcium relationship [3, 29].
  • •If PTH is elevated (or inappropriately normal) with hypercalcemia, calculate the calcium-to-creatinine clearance ratio (CCCR): (urine Ca × serum Cr) / (serum Ca × urine Cr). A CCCR <0.01 strongly suggests familial hypocalciuric hypercalcemia (FHH); a value >0.02 is typical of PHPT. Borderline cases (0.01-0.02) warrant an oral calcium suppression test or CASR genetic testing [3, 90].
  • •If PTH is suppressed (<20 pg/mL), measure PTHrP, 1,25-dihydroxyvitamin D, and 25-hydroxyvitamin D. Elevated PTHrP points to humoral hypercalcemia of malignancy (solid tumor). Elevated 1,25-dihydroxyvitamin D with suppressed PTHrP suggests granulomatous disease (sarcoidosis, tuberculosis) or lymphoma. Elevated 25-hydroxyvitamin D (>150 ng/mL) indicates vitamin D intoxication [29, 80].
  • •If PTH and PTHrP are both low, with normal vitamin D metabolites, consider multiple myeloma (order serum protein electrophoresis, serum free light chains) or Addison disease [92, 93].
  • •For confirmed PHPT, obtain localization imaging before surgical referral: first-line high-resolution neck ultrasound (sensitivity 70-85%) plus 99mTc-sestamibi SPECT/CT (sensitivity 80-90%). If discordant or negative, obtain four-dimensional CT (4D-CT, sensitivity 85-95%) before referral [3, 78, 82].
  • •In suspected parathyroid carcinoma (severe hypercalcemia >14 mg/dL, palpable neck mass, hoarseness), proceed directly to en-bloc resection without preoperative biopsy; fine-needle aspiration risks tumor seeding. The diagnosis is histologic (capsular/vascular invasion, Ki-67 >5%) [84, 85].
  • •Order a 12-lead ECG at presentation: a QTc <360 ms in hypercalcemia warrants continuous telemetry for risk of ventricular arrhythmias [47, 50].

Management

  • •Classify severity by corrected calcium and symptoms. Severe (≥14 mg/dL or symptomatic): admit to ICU. Moderate (12-13.9 mg/dL): admit to medical ward. Mild (10.5-11.9 mg/dL): may manage as outpatient if cause known and stable [38, 99].
  • •Initiate IV normal saline for volume expansion: bolus 200-500 mL/h over 1-2 hours, then 100-200 mL/h to target urine output 100-150 mL/h. This corrects dehydration, enhances urinary calcium excretion, and lowers calcium by 1-2 mg/dL within 24-48 hours. Caution in heart failure or severe renal impairment, consider central venous pressure monitoring [39].
  • •Add calcitonin for rapid but transient reduction: 4-8 IU/kg IM or SC every 6-12 hours. Onset of action is 2-4 hours, but tachyphylaxis develops after 48 hours due to receptor downregulation. Use as a bridge while bisphosphonates take effect [115].
  • •Administer a bisphosphonate as definitive first-line antiresorptive therapy: zoledronic acid 4 mg IV over 15 minutes (preferred for malignancy; lowers calcium by 1-2 mg/dL within 2-4 days, nadir at 4-7 days) or pamidronate 60-90 mg IV over 2-4 hours. Avoid zoledronic acid if creatinine clearance <35 mL/min; use denosumab instead [38, 106].
  • •For bisphosphonate-refractory hypercalcemia or when bisphosphonates are contraindicated (e.g., CKD), administer denosumab 120 mg SC. In a single-arm study, 80% of patients with persistent hypercalcemia despite bisphosphonates achieved a response (corrected Ca <11.5 mg/dL) within 10 days; median response duration 104 days [119].
  • •For hypercalcemia driven by elevated 1,25-dihydroxyvitamin D (granulomatous disease, lymphoma, vitamin D intoxication), start glucocorticoids: prednisone 0.5-1 mg/kg/day (or hydrocortisone 100-200 mg IV every 6 hours). Onset of action is 3-5 days; 90% of patients with sarcoidosis respond within 1 week [29, 80].
  • •Reserve dialysis with a low-calcium dialysate (1.0-1.25 mmol/L) for severe, refractory hypercalcemia, especially with acute kidney injury or volume overload [108, 112].
  • •Monitor corrected calcium every 6-12 hours initially, then daily once stable. Also monitor serum creatinine, magnesium, potassium, and phosphate. Adjust IV fluid rate based on urine output and volume status [38, 39].
  • •Treatment failure protocol: if corrected calcium has not decreased by ≥1 mg/dL after 48 hours of fluids plus bisphosphonate, add calcitonin (if not already used), consider denosumab 120 mg SC, re-evaluate the underlying cause, and proceed to dialysis if calcium continues to rise [119].
  • •What NOT to do: Do NOT administer phosphate supplements, they can precipitate calcium phosphate crystals in renal tubules. Do NOT use loop diuretics (e.g., furosemide) unless volume overloaded, they exacerbate dehydration. Do NOT use bisphosphonates in acute renal failure; denosumab is preferred. Do NOT rely on calcitonin as monotherapy for sustained control [114, 109].
  • •For long-term management of PHPT: parathyroidectomy is the only curative therapy, indicated for all symptomatic patients and for asymptomatic patients meeting any Endocrine Society criterion (Ca >1 mg/dL above ULN, CrCl <60 mL/min, T-score ≤-2.5, age <50). Cure rate >95% at 10 years in experienced hands [38, 78].
  • •For PHPT patients who are not surgical candidates, start cinacalcet 30 mg PO twice daily, titrate every 2-4 weeks to a maximum of 90 mg QID to maintain serum Ca within the normal range (target 8.5-10.2 mg/dL). In Phase 3 trials, 84% achieved normocalcemia at 28 weeks [118].
  • •For hypercalcemia of malignancy, continue bisphosphonates or denosumab for long-term suppression. Recheck corrected calcium every 2-4 weeks for the first 3 months, then every 3 months. Re-treat when corrected calcium rises above 11.0 mg/dL. Consider adding zoledronic acid 4 mg IV monthly or denosumab 120 mg SC every 4 weeks for skeletal-related event prevention [38, 123].
  • •Refer all patients with PHPT who meet surgical criteria to an experienced endocrine surgeon. Refer patients with suspected parathyroid carcinoma to a high-volume center for en-bloc resection. Refer patients with FHH or MEN1 for genetic counseling and cascade screening [3, 85].

Board Review — High Yield

  • •PTH level, single most important test: elevated/inappropriately normal = PTH-dependent (PHPT, FHH, lithium); suppressed = PTH-independent (malignancy, granulomatous, vitamin D intoxication).
  • •CCCR <0.01, hallmark of familial hypocalciuric hypercalcemia (FHH); distinguishes it from PHPT before unnecessary surgery.
  • •Humoral hypercalcemia of malignancy (HHM), mediated by PTHrP from solid tumors (squamous cell lung, breast, renal); signature: suppressed PTH, elevated PTHrP, low 1,25(OH)2D.
  • •Calcitriol-mediated hypercalcemia, driven by extrarenal 1α-hydroxylase in granulomatous disease (sarcoidosis, TB); signature: suppressed PTH, normal PTHrP, elevated 1,25(OH)2D.
  • •Severe hypercalcemia (≥14 mg/dL), medical emergency: ICU, IV fluids, calcitonin (rapid but transient), bisphosphonate (zoledronic acid 4 mg IV), consider denosumab or dialysis.
  • •Parathyroid carcinoma, suspect in severe hypercalcemia >14 mg/dL with palpable neck mass or hoarseness; en-bloc resection without preoperative biopsy is standard.
  • •Cinacalcet, calcimimetic for PHPT patients who cannot undergo surgery; start 30 mg PO BID, titrate to normocalcemia.
  • •Do NOT give phosphate, precipitates calcium phosphate crystals causing acute phosphate nephropathy.
  • •Primary hyperparathyroidism, most common cause in outpatients; surgery is curative in >95% when criteria met.
  • •Multiple myeloma, hypercalcemia in 15-20% at diagnosis; part of CRAB criteria; managed with systemic therapy and bisphosphonates.

Deep Dive — Evidence Details

References

  1. [1]

    Marx SJ. “New Concepts About Familial Isolated Hyperparathyroidism.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30848815 ↗

    L5OTHERCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation
  2. [2]

    Hong N, Yoon HJ, Lee YH et al.. “Serum PTHrP Predicts Weight Loss in Cancer Patients Independent of Hypercalcemia, Inflammation, and Tumor Burden.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26765580 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature
  3. [3]

    Bollerslev J, Rejnmark L, Zahn A et al.. “European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders.” European journal of endocrinology (2022). PMID: 34863037 ↗

    L1OTHERCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  4. [4]

    Do Cao C, Christou N, Hadoux J et al.. “Chapter 8: Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor.” Annales d'endocrinologie (2025). PMID: 39818300 ↗

    L1GUIDELINECited in: Definition, Classification and Axis Nomenclature
  5. [5]

    Macherey S, Monsef I, Jahn F et al.. “Bisphosphonates for advanced prostate cancer.” The Cochrane database of systematic reviews (2017). PMID: 29278410 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  6. [6]

    Holm M, Vestergaard P, Poulsen MM et al.. “Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Population-Based Retrospective Study.” Cancers (2023). PMID: 37046785 ↗

    L3COHORTCited in: Definition, Classification and Axis Nomenclature
  7. [7]

    Ha M, Jeong H, Roh JS et al.. “DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.” Urologic oncology (2019). PMID: 31377166 ↗

    L3COHORTCited in: Definition, Classification and Axis Nomenclature
  8. [8]

    Ucan B, Ata N, Kizilgul M et al.. “Importance of Hypomagnesemia in Primary Hyperparathyroidism: A Turkish Nationwide Retrospective Cohort Study.” Biological trace element research (2024). PMID: 39666169 ↗

    L3COHORTCited in: Definition, Classification and Axis Nomenclature
  9. [9]

    Turan I, Atar M, Eltan M et al.. “Targeting Hypercalciuria in SLC34A1-Related Disorders: Impact of Oral Phosphate Therapy and Novel Genetic Insights in Pediatric Case Series.” Calcified tissue international (2026). PMID: 41543768 ↗

    L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature
  10. [10]

    Townsend KS, Johnson PJ, Donnelly LL et al.. “Concurrent chronic lymphocytic leukemia and primary hyperparathyroidism in a mule.” Journal of veterinary internal medicine (2023). PMID: 37118906 ↗

    L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature
  11. [11]

    Heck A, Pretorius M, Lundstam K et al.. “No effect of surgery on kidney and cardiovascular risk factors in mild primary hyperparathyroidism: secondary analyses from a 10-year randomized controlled trial.” European journal of endocrinology (2024). PMID: 39189547 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  12. [12]

    Roizen J, Levine MA. “A meta-analysis comparing the biochemistry of primary hyperparathyroidism in youths to the biochemistry of primary hyperparathyroidism in adults.” The Journal of clinical endocrinology and metabolism (2014). PMID: 25181388 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation
  13. [13]

    Charoenngam N, Wattanachayakul P, Mannstadt M. “CASRdb: A Publicly Accessible Comprehensive Database for Disease-Associated Calcium-Sensing Receptor Variants.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39484850 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  14. [14]

    Vellanki P, Lange K, Elaraj D et al.. “Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24178790 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  15. [15]

    Gannon AW, Monk HM, Levine MA. “Cinacalcet monotherapy in neonatal severe hyperparathyroidism: a case study and review.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24203066 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  16. [16]

    Haissaguerre M, Louiset E, Juhlin CC et al.. “Immunohistochemical characterization of a steroid-secreting oncocytic adrenal carcinoma responsible for paraneoplastic hyperparathyroidism.” European journal of endocrinology (2023). PMID: 36869749 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  17. [17]

    Song L, Liu L, Miller RT et al.. “Glucocorticoid-responsive lymphocytic parathyroiditis and hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor: a case report and literature review.” European journal of endocrinology (2017). PMID: 28515208 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  18. [18]

    Sølling ASK, Tougaard BG, Harsløf T et al.. “Non-parathyroid hypercalcemia associated with paraffin oil injection in 12 younger male bodybuilders: a case series.” European journal of endocrinology (2018). PMID: 29599408 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  19. [19]

    Motlaghzadeh Y, Bilezikian JP, Sellmeyer DE. “Rare Causes of Hypercalcemia: 2021 Update.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34240162 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  20. [20]

    Bikle D. “Nonclassic actions of vitamin D.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18854395 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  21. [21]

    Wysolmerski JJ. “Parathyroid hormone-related protein: an update.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22745236 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  22. [22]

    Marx SJ. “Uncoupling of secretion from growth in some hormone secretory tissues.” The Journal of clinical endocrinology and metabolism (2014). PMID: 25004249 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  23. [23]

    Anastasilakis AD, Yavropoulou MP, Palermo A et al.. “Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?” European journal of endocrinology (2024). PMID: 38938063 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  24. [24]

    Montero-Lopez R, Ludwig K, Jacobs B et al.. “Metaphyseal band fractures in pediatric patients treated with denosumab.” European journal of endocrinology (2025). PMID: 41208398 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  25. [25]

    Mayr B, Schnabel D, Dörr HG et al.. “GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts.” European journal of endocrinology (2015). PMID: 26646938 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  26. [26]

    Storvall S, Leijon H, Ryhänen EM et al.. “Filamin A and parafibromin expression in parathyroid carcinoma.” European journal of endocrinology (2021). PMID: 34606470 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  27. [27]

    Nesbit MA, Hannan FM, Howles SA et al.. “Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia.” The New England journal of medicine (2013). PMID: 23802516 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  28. [28]

    Clemenceau A, Bherer J, Grimshaw A et al.. “Clinical and prognostic significance of parathyroid hormone-related protein in breast cancer: a systematic review and meta-analyses of observational studies in women.” Endocrine-related cancer (2026). PMID: 41700599 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
  29. [29]

    Tebben PJ, Singh RJ, Kumar R. “Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.” Endocrine reviews (2016). PMID: 27588937 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  30. [30]

    Jakob T, Tesfamariam YM, Macherey S et al.. “Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.” The Cochrane database of systematic reviews (2020). PMID: 33270906 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  31. [31]

    Manfredi G, Turisani A, Piasentier A et al.. “A Case of Tumor-Induced Osteomalacia Masked by Parathyroid Carcinoma.” Journal of clinical medicine (2026). PMID: 42279228 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  32. [32]

    Hu D, Li Y, Shen S. “Case Report: A 69-year-old woman with dermatopathic lymphadenopathy and hypercalcemia after COVID-19 infection.” Frontiers in immunology (2026). PMID: 41859087 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  33. [33]

    Hobbs A, Nair R, Ludwig K et al.. “Denosumab as a treatment for pediatric hypercalcemia-a multicenter experience.” JBMR plus (2025). PMID: 41522662 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  34. [34]

    Zdziarski P. “Critical Literature Review on Clinical Presentation of Oncocytic Thyroid Carcinoma with Immunoendocrine Complications and Unpredictable Outcome: Myths, Facts, and Their Overinterpretation.” Biomedicines (2026). PMID: 42351763 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  35. [35]

    Bohne SM, Wegwitz F, Kruse-Wieczorek J et al.. “PTHrP-associated hypercalcemia in gynecologic malignancies: a scoping review.” Archives of gynecology and obstetrics (2026). PMID: 42307672 ↗

    L3REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  36. [36]

    Stokar J, Szalat A. “Risk of medication-related osteonecrosis of the jaw during romosozumab treatment.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 42303774 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  37. [37]

    Forțofoiu D, Sacerdoțianu VM, Șerban RE et al.. “Paraneoplastic Endocrine Changes in Gastrointestinal Tumors: A Clinical and Mechanistic Review.” International journal of molecular sciences (2026). PMID: 42278207 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  38. [38]

    El-Hajj Fuleihan G, Clines GA, Hu MI et al.. “Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36545746 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  39. [39]

    Seisa MO, Nayfeh T, Hasan B et al.. “A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36545700 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae
  40. [40]

    Orloff LA, Wiseman SM, Bernet VJ et al.. “American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 29848235 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  41. [41]

    Pepe J, Cipriani C, Curione M et al.. “Reduction of arrhythmias in primary hyperparathyroidism, by parathyroidectomy, evaluated with 24-h ECG monitoring.” European journal of endocrinology (2018). PMID: 29875287 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors
  42. [42]

    Manson JE, Cook NR, Lee IM et al.. “Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.” The New England journal of medicine (2018). PMID: 30415629 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  43. [43]

    Goudet P, Bonithon-Kopp C, Murat A et al.. “Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines.” European journal of endocrinology (2011). PMID: 21551167 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  44. [44]

    Glasgow C, Lau EYC, Aloj L et al.. “An Approach to a Patient With Primary Hyperparathyroidism and a Suspected Ectopic Parathyroid Adenoma.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35150267 ↗

    L4CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors
  45. [45]

    Szalat A, Mazeh H, Freund HR. “Lithium-associated hyperparathyroidism: report of four cases and review of the literature.” European journal of endocrinology (2008). PMID: 19001061 ↗

    L4CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  46. [46]

    Livadariu E, Auriemma RS, Rydlewski C et al.. “Mutations of calcium-sensing receptor gene: two novel mutations and overview of impact on calcium homeostasis.” European journal of endocrinology (2011). PMID: 21566074 ↗

    L4CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  47. [47]

    Pepe J, Minisola S, Ettorre E et al.. “Cardiovascular Involvement in Primary Hyperparathyroidism.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41239190 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  48. [48]

    Obi Y, Mehrotra R, Rivara MB et al.. “Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients.” The Journal of clinical endocrinology and metabolism (2016). PMID: 27045726 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors
  49. [49]

    Vogiatzi MG, Jacobson-Dickman E, DeBoer MD. “Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24456284 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  50. [50]

    Pepe J, Cipriani C, Sonato C et al.. “Cardiovascular manifestations of primary hyperparathyroidism: a narrative review.” European journal of endocrinology (2017). PMID: 28864535 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  51. [51]

    Schlingmann KP, Kaufmann M, Weber S et al.. “Mutations in CYP24A1 and idiopathic infantile hypercalcemia.” The New England journal of medicine (2011). PMID: 21675912 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  52. [52]

    Li C, Xu S, Wang Y et al.. “The role of nutritional vitamin D on microinflammation and nutritional status in maintenance hemodialysis patients: a meta-analysis of randomized controlled trials.” Frontiers in nutrition (2026). PMID: 42293210 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
  53. [53]

    Padmakar S. “Clinical Spectrum and Management of Hypervitaminosis A: A Systematic Review of Case-Based Evidence.” Clinica chimica acta; international journal of clinical chemistry (2026). PMID: 42176931 ↗

    L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  54. [54]

    Fisch SA, Zilberman S, Tudor A et al.. “Secondary and Tertiary Hyperparathyroidism among Patients with X-Linked Hypophosphatemia: A Systematic Review and Meta-analysis.” Calcified tissue international (2025). PMID: 41437161 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  55. [55]

    Mhaskar R, Kumar A, Miladinovic B et al.. “Bisphosphonates in multiple myeloma: an updated network meta-analysis.” The Cochrane database of systematic reviews (2017). PMID: 29253322 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  56. [56]

    Mhaskar R, Redzepovic J, Wheatley K et al.. “Bisphosphonates in multiple myeloma: a network meta-analysis.” The Cochrane database of systematic reviews (2012). PMID: 22592688 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  57. [57]

    Pedrazzini A, Suravaram V, Lu VYZ et al.. “Outcomes and safety of antibiotic-loaded calcium sulfate beads in orthopaedics: A systematic review and meta-analysis.” Journal of orthopaedics (2026). PMID: 42100185 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  58. [58]

    Cuenca-Pardo J, Ramos-Gallardo GO, Lira-Álvarez M et al.. “Breast implant explantation and capsulectomy in symptomatic patients. Is there any improvement with the procedure? Systematic review and meta-analysis.” JPRAS open (2026). PMID: 42099752 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  59. [59]

    Anantyo DT, Oktaviana M, Sandradewi KM. “Hypercalcemia in neonatal subcutaneous fat necrosis: A systematic review of risk factors, timing, and complications.” Journal of neonatal-perinatal medicine (2026). PMID: 42018434 ↗

    L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  60. [60]

    Jiang Y, Zeng Y, Xin L et al.. “Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study.” Journal of bone and mineral metabolism (2026). PMID: 42303801 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  61. [61]

    Tachamo N, Donato A, Timilsina B et al.. “Hypercalcemia associated with cosmetic injections: a systematic review.” European journal of endocrinology (2018). PMID: 29453201 ↗

    L4SR_OBSCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  62. [62]

    Cappellani D, Brancatella A, Morganti R et al.. “Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review.” European journal of endocrinology (2021). PMID: 34735369 ↗

    L4SR_OBSCited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  63. [63]

    Frederiksen A, Rossing M, Hermann P et al.. “Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30990521 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  64. [64]

    Sundaresh V, Levine SN. “From hypocalcemia to hypercalcemia-an unusual clinical presentation of a patient with permanent postsurgical hypoparathyroidism.” The Journal of clinical endocrinology and metabolism (2015). PMID: 25303492 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  65. [65]

    Hawkes CP, Levine MA. “Ketotic hypercalcemia: a case series and description of a novel entity.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24606099 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  66. [66]

    Kawashima S, Nakamura A, Inoue T et al.. “Maternal Uniparental Disomy for Chromosome 20: Physical and Endocrinological Characteristics of Five Patients.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29878129 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  67. [67]

    Grunewald TG, von Luettichau I, Welsch U et al.. “First report of ectopic ACTH syndrome and PTHrP-induced hypercalcemia due to a hepatoblastoma in a child.” European journal of endocrinology (2010). PMID: 20133447 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  68. [68]

    Bilezikian JP. “Primary Hyperparathyroidism.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30060226 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  69. [69]

    Orita Y, Sugitani I, Toda K et al.. “Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.” Thyroid : official journal of the American Thyroid Association (2010). PMID: 21058881 ↗

    L2OTHERCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  70. [70]

    Tulelli B, Besançon A, Stoupa A et al.. “Synchronous bilateral adrenalectomy for ACTH-independent Cushing's syndrome in children: multidisciplinary management.” European journal of endocrinology (2024). PMID: 39676528 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  71. [71]

    Bomhof G, Verhave J, Stegeman C et al.. “A retrospective multicenter cohort study of patients with sarcoidosis and renal involvement.” BMC nephrology (2026). PMID: 41578220 ↗

    L2COHORTCited in: Clinical Presentation
  72. [72]

    Vuksanović M, Kovačević B, Kuzmanović J et al.. “Pathological fracture following minimal trauma as the initial presentation of parathyroid carcinoma-associated hyperparathyroidism in a young man: a case report.” Frontiers in endocrinology (2026). PMID: 42181202 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  73. [73]

    Deng C, Huang C, Su X. “From persistent hypercalcemia to parathyroid carcinoma: a case report of acute urinary retention and the diagnostic role of Ki-67.” Frontiers in medicine (2026). PMID: 42158131 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  74. [74]

    Lin J, Wang TS, Donahue A et al.. “Clinical and molecular characterization of familial hypocalciuric hypercalcemia in an endocrine practice: a case series of 25 patients.” JBMR plus (2026). PMID: 42038813 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  75. [75]

    Ahel IB, Andritsos V, Košuljandić Đ et al.. “Case Report: Two infants with hypercalcemia of rare and distinct etiologies.” Frontiers in endocrinology (2026). PMID: 41982776 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  76. [76]

    Deng P, Wang Q, Huang M et al.. “Case Report: Developmental-like skeletal deformities and transient osteosclerosis as rare presentations of primary hyperparathyroidism.” Frontiers in endocrinology (2026). PMID: 41767373 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Complications and Long-term Sequelae
  77. [77]

    Wagner H, Alvarsson M, Mannheimer B et al.. “No Effect of High-Dose Vitamin D Treatment on β-Cell Function, Insulin Sensitivity, or Glucose Homeostasis in Subjects With Abnormal Glucose Tolerance: A Randomized Clinical Trial.” Diabetes care (2016). PMID: 26786573 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  78. [78]

    Zaman M, Raveendran L, Senay A et al.. “Long-term Recurrence Rates After Surgery in Primary Hyperparathyroidism.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37279502 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  79. [79]

    Jacobs TP, Kaufman M, Jones G et al.. “A lifetime of hypercalcemia and hypercalciuria, finally explained.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24423361 ↗

    L5CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  80. [80]

    Kallas M, Green F, Hewison M et al.. “Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20427501 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  81. [81]

    Brancatella A, Cappellani D, Kaufmann M et al.. “Long-term Efficacy and Safety of Rifampin in the Treatment of a Patient Carrying a CYP24A1 Loss-of-Function Variant.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35569070 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  82. [82]

    Magalhães PK, Antonini SR, de Paula FJ et al.. “Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 21449769 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  83. [83]

    Ono Y, Oda N, Ishihara S et al.. “Insulinoma cell calcium-sensing receptor influences insulin secretion in a case with concurrent familial hypocalciuric hypercalcemia and malignant metastatic insulinoma.” European journal of endocrinology (2008). PMID: 18430790 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  84. [84]

    Cetani F, Pardi E, Torregrossa L et al.. “Approach to the Patient With Parathyroid Carcinoma.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37531615 ↗

    L5OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  85. [85]

    Song JX, Xie J, Zhou JX et al.. “Approach to the Patient With Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40878942 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  86. [86]

    Eastell R, Arnold A, Brandi ML et al.. “Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19193909 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  87. [87]

    Grant P, Velusamy A. “What is the best way of assessing neurocognitive dysfunction in patients with primary hyperparathyroidism?” The Journal of clinical endocrinology and metabolism (2013). PMID: 24203059 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  88. [88]

    Cardoso LM, Rolighed L, Amrein K et al.. “Advances in the clinical management of parathyroid disorders: report from the 2024 workshop by the ESE educational program on parathyroid disorders.” European journal of endocrinology (2025). PMID: 41032657 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
  89. [89]

    García-Castaño A, Madariaga L, Pérez de Nanclares G et al.. “Novel mutations associated with inherited human calcium-sensing receptor disorders: A clinical genetic study.” European journal of endocrinology (2019). PMID: 30407919 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  90. [90]

    Kou L, Song A, Nie M et al.. “Clinical and Genetic Profile of Chinese Familial Hypocalciuric Hypercalcemia Type 1 (FHH1): A Retrospective Study.” Endocrine (2026). PMID: 41920387 ↗

    L3COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  91. [91]

    Tantikittipisut P, Thangpong R, Kor-anantakul P et al.. “Blau syndrome initially manifested with hypercalcemia: a case report and literature review.” Annals of pediatric endocrinology & metabolism (2026). PMID: 42205009 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  92. [92]

    Andrunache A, Himcinschi ME, Barbu S et al.. “CNS Involvement of Multiple Myeloma-A Case Series and Narrative Literature Review.” Journal of clinical medicine (2026). PMID: 42194889 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  93. [93]

    Segev N, Wilson E, Moehlman M et al.. “Unmasking Adrenal Insufficiency: Adrenal Crisis Triggered by Influenza-Associated Encephalitis.” Pediatrics (2026). PMID: 42014096 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention
  94. [94]

    Gilchrist NL, Frampton CM, Acland RH et al.. “Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17227802 ↗

    L1RCTCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
  95. [95]

    Peacock M, Bilezikian JP, Bolognese MA et al.. “Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20943783 ↗

    L2RCTCited in: Severity, Staging and Risk Stratification
  96. [96]

    Mitchell D, Jordan M, Gehman S et al.. “Treatment of Children and Adults With X-Linked Hypophosphatemia With Calcitriol Alone: A Prospective, Open-Label Study.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41137448 ↗

    L2TRIAL_NONRANDOMCited in: Severity, Staging and Risk Stratification, Complications and Long-term Sequelae
  97. [97]

    Berruti A, Libè R, Laganà M et al.. “Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study.” European journal of endocrinology (2019). PMID: 30970324 ↗

    L3COHORTCited in: Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  98. [98]

    Zajickova K, Vrbikova J, Canaff L et al.. “Identification and functional characterization of a novel mutation in the calcium-sensing receptor gene in familial hypocalciuric hypercalcemia: modulation of clinical severity by vitamin D status.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17473068 ↗

    L4CASE_REPORTCited in: Severity, Staging and Risk Stratification
  99. [99]

    Donovan PJ, Achong N, Griffin K et al.. “PTHrP-mediated hypercalcemia: causes and survival in 138 patients.” The Journal of clinical endocrinology and metabolism (2015). PMID: 25719931 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
  100. [100]

    Kim HK, Bae WK, Choi YD et al.. “Serum calcitonin may falsely estimate tumor burden in chronic hypercalcemia: a case of prostatic and multiple bone metastases from medullary thyroid cancer.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23985043 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention
  101. [101]

    Zhu CY, Zhou HX, Tseng CH et al.. “Long-term effects of primary hyperparathyroidism and parathyroidectomy on kidney function.” European journal of endocrinology (2023). PMID: 37449311 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification
  102. [102]

    Glaudo M, Letz S, Quinkler M et al.. “Heterozygous inactivating CaSR mutations causing neonatal hyperparathyroidism: function, inheritance and phenotype.” European journal of endocrinology (2016). PMID: 27666534 ↗

    L5OTHERCited in: Severity, Staging and Risk Stratification
  103. [103]

    Gieszinger G, Kui B, Hegyi P et al.. “Hypercalcemia Causes More Severe Acute Pancreatitis: An International Multicenter Cohort Study.” Journal of clinical medicine (2025). PMID: 40944062 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification
  104. [104]

    Li X, Wang H, Li Y et al.. “The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.” BMC cancer (2025). PMID: 41430153 ↗

    L3COHORTCited in: Severity, Staging and Risk Stratification
  105. [105]

    Hao L, Huang N, Tao Y et al.. “ALPL Mutations With Dominant-Negative Effect in Infantile Hypophosphatasia Monozygotic Twins.” Human mutation (2026). PMID: 41993131 ↗

    L4CASE_REPORTCited in: Severity, Staging and Risk Stratification
  106. [106]

    Liu J, Lin X, Sun L et al.. “Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38198649 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  107. [107]

    D'Amour P, Räkel A, Brossard JH et al.. “Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH(1-84) ratios derived from three generations of PTH assays.” The Journal of clinical endocrinology and metabolism (2005). PMID: 16219713 ↗

    L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies
  108. [108]

    Whyte MP, Leelawattana R, Reinus WR et al.. “Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24064686 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  109. [109]

    Booth KA, Hays CI. “Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.” The Journal of clinical endocrinology and metabolism (2014). PMID: 25033064 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  110. [110]

    Brancatella A, Cappellani D, Kaufmann M et al.. “Do the Heterozygous Carriers of a CYP24A1 Mutation Display a Different Biochemical Phenotype Than Wild Types?” The Journal of clinical endocrinology and metabolism (2021). PMID: 33249478 ↗

    L3CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  111. [111]

    Winter EM, Appelman-Dijkstra NM. “Parathyroid Hormone-Related Protein-Induced Hypercalcemia of Pregnancy Successfully Reversed by a Dopamine Agonist.” The Journal of clinical endocrinology and metabolism (2017). PMID: 29053801 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  112. [112]

    Volety A, Shaffer N, Biard L et al.. “Kidney Transplant Complicated by Severe Parathyroid Hormone-Independent Hypercalcemia From Tumoral Calcinosis.” Kidney medicine (2026). PMID: 42179806 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  113. [113]

    Arrabito M, Cannata E, Samperi P et al.. “CD19-Negative Acute Lymphoblastic Leukemia (ALL): A Case Report and Review of Literature on a Rare Phenomenon De Novo and a Future Induced Struggle in Relapse.” International journal of molecular sciences (2026). PMID: 41977386 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  114. [114]

    Zhu S, Sun L, Kuang X et al.. “Successful treatment of pediatric acute phosphate nephropathy: a case report and literature review.” Frontiers in medicine (2026). PMID: 41958594 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  115. [115]

    Ben Dori S, Kabaha N, Abu Husseine A et al.. “Beyond Malignancy: Clinical Insights from Three Cases of Severe Hypercalcemia.” Journal of clinical medicine (2026). PMID: 41899334 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  116. [116]

    Krishnan N, Perazella MA. “Diagnosis and Management of Acute and Chronic Lithium-Associated Nephrotoxicity.” Journal of the American Society of Nephrology : JASN (2026). PMID: 42247265 ↗

    L5OTHERCited in: Acute Management and Endocrine Emergencies
  117. [117]

    Pittas AG, Dawson-Hughes B, Sheehan PR et al.. “Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial.” Diabetes care (2014). PMID: 25205139 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  118. [118]

    Khan A, Bilezikian J, Bone H et al.. “Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.” European journal of endocrinology (2015). PMID: 25637076 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  119. [119]

    Hu MI, Glezerman IG, Leboulleux S et al.. “Denosumab for treatment of hypercalcemia of malignancy.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24915117 ↗

    L2TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  120. [120]

    Bassatne A, Murad MH, Piggott T et al.. “Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36545699 ↗

    L5SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  121. [121]

    Walker Harris V, Jan De Beur S. “Postoperative hypoparathyroidism: medical and surgical therapeutic options.” Thyroid : official journal of the American Thyroid Association (2009). PMID: 19731978 ↗

    L5OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  122. [122]

    Huber A, Demarchi M, Verissimo T et al.. “Primary hyperparathyroidism induces erythropoietin resistance through fibroblast growth factor 23.” European journal of endocrinology (2025). PMID: 40067841 ↗

    L2OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  123. [123]

    Mhaskar R, Redzepovic J, Wheatley K et al.. “Bisphosphonates in multiple myeloma.” The Cochrane database of systematic reviews (2010). PMID: 20238320 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  124. [124]

    Martinez-Zapata MJ, Roqué M, Alonso-Coello P et al.. “Calcitonin for metastatic bone pain.” The Cochrane database of systematic reviews (2006). PMID: 16856000 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  125. [125]

    Zhang LW, Huang A, Ma HF et al.. “Network meta-analysis of bisphosphonates in the treatment of bone metastases from breast cancer.” International journal of clinical pharmacology and therapeutics (2026). PMID: 42290268 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  126. [126]

    Szymczuk V, Elbashir II, Ahmed R et al.. “Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39673171 ↗

    L2TRIAL_NONRANDOMCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  127. [127]

    Demir K, Yildiz M, Bahat H et al.. “Clinical Heterogeneity and Phenotypic Expansion of NaPi-IIa-Associated Disease.” The Journal of clinical endocrinology and metabolism (2017). PMID: 29029121 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  128. [128]

    Gild ML, Tsang V, Samra J et al.. “Hypercalcemia in Glucagon Cell Hyperplasia and Neoplasia (Mahvash Syndrome): A New Association.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30032256 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  129. [129]

    Falchetti A, Gozzini A, Terranegra A et al.. “A novel germline inactivating mutation in the CASR gene in an Italian kindred affected by familial hypocalciuric hypercalcemia.” European journal of endocrinology (2012). PMID: 22315359 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  130. [130]

    Eller-Vainicher C, Ossola MW, Beck-Peccoz P et al.. “PTHrP-associated hypercalcemia of pregnancy resolved after delivery: a case report.” European journal of endocrinology (2012). PMID: 22247017 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  131. [131]

    Kumar S, Girgis CM, Tran B et al.. “Burosumab in adults with X-linked hypophosphatemia: real-world experience from a retrospective study in Sydney.” JBMR plus (2025). PMID: 41445548 ↗

    L3COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  132. [132]

    Yau V, Best DL. “Efficacy of Denosumab for Treatment of Pain in Fibrous Dysplasia and McCune-Albright Syndrome: A Systematic Review.” Clinical endocrinology (2026). PMID: 41858142 ↗

    L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  133. [133]

    Raeder H, Shaw N, Netelenbos C et al.. “A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.” European journal of endocrinology (2008). PMID: 18775977 ↗

    L4CASE_REPORTCited in: Complications and Long-term Sequelae
  134. [134]

    Bollerslev J, Schalin-Jäntti C, Rejnmark L et al.. “MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.” European journal of endocrinology (2019). PMID: 31176307 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  135. [135]

    Alzahrani HA. “Case Report: An undescended intravagal parathyroid adenoma: a rare cause of refractory primary hyperparathyroidism and severe osteoporosis.” Frontiers in endocrinology (2026). PMID: 41788776 ↗

    L4CASE_REPORTCited in: Complications and Long-term Sequelae
  136. [136]

    Modarressi T, Levine MA, Tchou J et al.. “Gestational Gigantomastia Complicated by PTHrP-Mediated Hypercalcemia.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30032172 ↗

    L4CASE_REPORTCited in: Prognosis, Natural History, Special Populations and Prevention
  137. [137]

    Schini M, Jacques RM, Oakes E et al.. “Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32072184 ↗

    L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention
  138. [138]

    Khan AA, Clarke B, Rejnmark L et al.. “MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management.” European journal of endocrinology (2019). PMID: 30444723 ↗

    L1REVIEW_NARRATIVECited in: Prognosis, Natural History, Special Populations and Prevention

Revision History

All updates applied to this page

Loading revisions…